Stantec helping Vermont Tech build new fire training facility

first_imgStantec helping Vermont Tech build new fire training facilityNORTH SPRINGFIELD VT (July 22, 2008) TSX:STN; NYSE:SXCLocal engineering firm Stantec is helping Vermont Technical College build new training equipment for its Fire Science degree program.Engineers from the company’s North Springfield and South Burlington offices are designing the site’s new access road, parking, water main and storage tank, and electrical services for the equipment, which will serve as a “live-burn” training center for firefighters in training at Vermont Tech, the Vermont Fire Academy and local community fire departments. Stantec is also managing the site’s permitting, including that related to Act 250 and stormwater management.The work is being funded primarily by a $406,000 federal grant secured earlier this year by Senator Bernie Sanders to purchase equipment; and a $240,000 state grant to erect the facility. Under conditions of the grant, Stantec and the college must complete the project by the end of 2008.”We’re really excited to be helping make such important training available to Vermont’s firefighters,” said Tom Nesbitt, a senior associate at Stantec. “The project’s very tight timeframe is a challenge, but our team is ready and able to put in all the hours we need to complete the work safely, efficiently, and within the deadline.”In 1997, Stantec also provided structural and civil engineering services for a similar facility in Concord, New Hampshire.Started in 2007, Vermont Tech’s Fire Science program prepares students for careers in fire protection, including professional firefighters, emergency medical technicians, and dispatchers. Students take courses in hazardous materials chemistry, fire prevention, and occupational safety and health.Stantec provides professional design and consulting services in planning, engineering, architecture, surveying, economics, and project management. We support public and private sector clients in a diverse range of markets in the infrastructure and facilities sector at every stage, from initial concept and financial feasibility to project completion and beyond. Our services are offered through approximately 9,000 employees operating out of more than 125 locations in North America. Stantec trades on the TSX under the symbol STN and on the NYSE under the symbol SXC.last_img read more

Daily use of aspirin does not reduce occurrence of major cardiovascular events

first_imgReviewed by James Ives, M.Psych. (Editor)Aug 28 2018The role of aspirin in preventing a first heart attack or stroke among people at moderate risk of heart disease remains unclear. At the 2018 European Society of Cardiology meeting, J. Michael Gaziano, MD, a preventive cardiologist at Brigham and Women’s Hospital, presented findings from ARRIVE, a randomized, controlled clinical trial of the use of daily aspirin to prevent a first cardiovascular event among more than 12,500 participants considered to be at moderate cardiovascular risk. The team’s findings are detailed in a paper published simultaneously in The Lancet.”Aspirin did not reduce the occurrence of major cardiovascular events in this study,” said Gaziano. “However, there were fewer events than expected, suggesting that this was in fact a low-risk population. This may have been because some participants were taking medications to lower blood pressure and lipids, which protected them from disease. The decision on whether to use aspirin for protection against cardiovascular disease should be made in consultation with a doctor, considering all the potential risks and benefits.”The benefits of taking aspirin to prevent a second or subsequent heart attack or stroke have been well established in previous studies but the effectiveness of taking aspirin to prevent a first cardiovascular event has been unclear, despite 30 years of randomized clinical trials. The Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE) study, sponsored by Bayer, sought to assess both the potential benefits as well as the risks to people at moderate risk of cardiovascular disease who may already be receiving some protection from modern preventative and therapeutic strategies.Participants were randomly assigned to receive either daily aspirin tablets (100 mg) or a placebo. A total of 12,546 participants were enrolled from primary care settings in the UK, Poland, Germany, Italy, Ireland, Spain, and the U.S. The primary endpoint was time to first occurrence of a composite of cardiovascular death, heart attack, unstable angina, stroke, and transient ischemic attack.Related StoriesResearchers report promising results of potential reversal agentStudy indicates the benefits of stopping aspirin in heart attack patientsAspirin could be used to treat patients with severe tuberculosis infectionThe rate of such cardiovascular events did not statistically differ between the aspirin group and the placebo group. During the study, 269 patients (4.29 percent) in the aspirin group and 281 patients (4.48 percent) in the placebo group experienced such cardiovascular events.Overall, these rates were lower than expected. The authors conclude that this may be reflective of contemporary risk-management strategies, such as the use of statins.Given that aspirin is known to increase patients’ risk of gastrointestinal bleeding, ARRIVE excluded patients at high risk of bleeding. It also excluded patients with diabetes. Gastrointestinal bleeding events (mostly mild) occurred in 61 patients in the aspirin group versus 29 in the placebo group. The overall incidence rate of adverse events was similar in both treatment groups.”The use of aspirin remains a decision that should involve a thoughtful discussion between a clinician and a patient, given the need to weigh cardiovascular and possible cancer prevention benefits against the bleeding risks, patient preferences, cost, and other factors,” the authors conclude.The authors’ declaration of interests and the roles of the Executive Committee and of the sponsor can be found in The Lancet. The sponsor was responsible for the conduct of the trial. The independent Executive Committee, of which Gaziano was a member, was responsible for the study protocol, oversight of the study, writing of the report, and the decision to publish the results. All members of the Executive Committee received personal fees from Bayer during the conduct of the study. Source: read more